Patents Assigned to The Institut National de la Santé et de la Recherche Médicale (INSERM)
  • Methods for cancer management targeting Co-029
    Patent number: 9040671
    Abstract: The present disclosure relates to a Co-029 inhibitor for inhibiting the migration of cancer cells which express Co-029. The disclosure relates to a Co-029 inhibitor for the treatment of cancer and/or the prevention of cancer metastasis and pharmaceutical compositions comprising said inhibitor and provides Co-029 antibodies. The disclosure provides a method for predicting the response of a patient afflicted with or susceptible to be afflicted with cancer to a medical treatment with a Co-029 inhibitor, a method for diagnosing a cancer in a patient and a method for predicting the survival in a cancer patient.
    Type: Grant
    Filed: July 22, 2011
    Date of Patent: May 26, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite de Paris X1 Paris Sud
    Inventors: Eric Rubinstein, Céline Greco, François Le Naour, Claude Boucheix
  • Nucleic acids targeting TCTP for use in the treatment of chemo- or hormone-resistant cancers
    Patent number: 9034840
    Abstract: The present invention concerns a TCTP antagonist, in particular a nucleic acid targeting an m RNA encoding Translationally-Controlled Tumor Protein (TCTP), wherein said nucleic acid is capable of reducing the amount of TCTP in cells, for use in the treatment or prevention of hormone-independent cancer or chemo-resistant cancer, such as an androgen-independent prostate cancer.
    Type: Grant
    Filed: December 19, 2011
    Date of Patent: May 19, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite de la Mediterrance Aix-Marseille II
    Inventors: Palma Rocchi, Virginie Baylot, Julie Acunzo, Claudia Andrieu, Maria Katsogiannou
  • Modified gram-negative bacteria for use as vaccines
    Patent number: 9034630
    Abstract: The invention relates to Gram-negative bacteria carrying an inactivated gene encoding a glycosyltransferase involved in the synthesis of the core of the LPS of said Gram-negative bacteria, wherein said inactivated gene results in the synthesis of a LPS having a modified core. These strains have an attenuated virulence but induce a humoral immunity sufficient for ensuring vaccination of the host.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: May 19, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique—CNRS, Université d'Aix Marseille, UNIVERSIDAD DE NAVARRA
    Inventors: Jean-Pierre Gorvel, Vilma Arce Gorvel, Maite Iriarte, Ignacio Moriyon, Raquel Conde-Alvarez
  • Kanamycin antisense nucleic acid for the treatment of cancer
    Patent number: 9029135
    Abstract: The invention relates to a nucleic acid comprising a sequence complementary to a fragment of the sequence coding for the kanamycin resistance protein. This nucleic acid is useful as a DNA vaccine adjuvant, and can be used e.g. for treating cancer, for example in combination with a non-immunosuppressive inducer of tumor cell apoptosis such as all-trans retinoic acid (ATRA).
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: May 12, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (Inserm), Universite Paris Diderot-Paris 7
    Inventors: Rose Ann Padua, Christine Chomienne
  • Method and kits for determining platelet susceptibility to activation in a patient
    Patent number: 9029095
    Abstract: The invention relates to methods and kits for determining platelet susceptibility to activation in a patient. More particularly, the present invention relates to a method for determining platelet susceptibility to activation in a patient, comprising a step consisting of measuring the level of GPVI dimers at the platelet surface in a blood sample obtained from said patient.
    Type: Grant
    Filed: December 1, 2011
    Date of Patent: May 12, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Paris Diderot
    Inventors: Martine Jandrot-Perrus, Laurent Feldman, Stéphane Loyau
  • Peptide capable of altering tubulin polymerization and use thereof for inhibiting cell proliferation
    Patent number: 9023806
    Abstract: The invention concerns a peptide derived from intermediate filaments and an intermediate filament fragment capable of altering tubulin polymerization and used for inhibiting cell proliferation, and more particularly for obtaining medicines designed to prevent or treat diseases involving cell proliferation, such as cancers for example.
    Type: Grant
    Filed: April 21, 2005
    Date of Patent: May 5, 2015
    Assignees: Universite d'Angers, Institut National de la Sante et de la Recherche Medicale (Inserm), McGill University
    Inventors: Arnaud Bocquet, Joël Eyer, Alan Peterson
  • Importation of mitochondrial protein by an enhanced allotopic approach
    Patent number: 9017999
    Abstract: The inventors demonstrate that mRNA sorting to the mitochondrial surface is an efficient way to proceed to such an allotopic expression, and that this mRNA sorting can be controlled by selecting appropriate mitochondrion-targeting sequence (MTS) and appropriate 3?UTR sequences. The CDS sequence which codes for the protein to be delivered into the mitochondrion is guided by these appropriate MTS and 3?UTR sequences from the nuclear compartment to the mitochondrion-bound polysomes (where the CDS is translated), and aids in an efficient translocation of a mature functional protein into the mitochondria. Appropriate MTS and 3?UTR sequences correspond to those of nuclearly-transcribed mitochondrially-targeted mRNAs. The inventors demonstrate that, to obtain a stable therapeutically-effective importation, both an appropriate MTS and an appropriate 3?UTR should preferably be used.
    Type: Grant
    Filed: May 3, 2006
    Date of Patent: April 28, 2015
    Assignee: Institut National de la Sante et de la Recherche Medicale (Inserm)
    Inventors: Marisol Corral-Debrinski, Jose-Alain Sahel, Valerie Kaltimbacher, Crystel Bonnet
  • METHODS AND KITS FOR PREDICTING THE RISK OF HAVING A CARDIOVASCULAR EVENT IN A SUBJECT
    Publication number: 20150104463
    Abstract: The present invention relates to in vitro methods and kits for predicting the risk of having a cardiovascular event in a subject. More particularly, the invention relates to an in vitro method for predicting the risk of a cardiovascular event in a subject, said method comprising the step of measuring the level of IL-17 in a blood sample obtained from said subject.
    Type: Application
    Filed: December 22, 2014
    Publication date: April 16, 2015
    Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), UNIVERSITE PARIS DESCARTES
    Inventors: Ziad MALLAT, Alain TEDGUI, Tabasomme SIMON, Nicolas DANCHIN
  • Sodium Thiosulphate for the Treatment of Ectopic Calcifications
    Publication number: 20150099013
    Abstract: The present invention relates to pharmaceutical compositions comprising sodium thiosulphate dispersed in a hydrophile-in-lipophile emulsion, and the use thereof for topical administration for the treatment of an ectopic calcification and/or of the consequences thereof in an individual, the sodium thiosulphate being in the form of a pharmaceutical composition comprising, in addition, a hydrophile-in-lipophile emulsion. The invention also relates to a method for preparing these pharmaceutical compositions.
    Type: Application
    Filed: May 10, 2013
    Publication date: April 9, 2015
    Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Voa Ratsimbazafy, Jeremy Jost, Vincent Guigonis, Eric Caudron
  • Therapeutic peptides and use thereof against huntington's disease
    Patent number: 8987211
    Abstract: Fusion proteins that contain the fusion of (i) a peptide of less than 100 amino acids comprising a first amino acid sequence comprising AASSG (SEQ ID NO: 1) and a second amino acid sequence comprising XAGXDXXTEXPXS (SEQ ID NO: 2), wherein X designates any amino acid, and (ii) a protein transduction domain (PTD) are provided, along with pharmaceutical compositions containing the fusion protein. The proteins can be used to treat Huntington's disease.
    Type: Grant
    Filed: April 12, 2012
    Date of Patent: March 24, 2015
    Assignees: Centre National de la Recherche Scientifique (CNRS), Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Montpellier 2 Sciences et Techniques
    Inventors: Florence Maschat, Marie-Laure Parmentier, Nathalie Bonneaud, Yoan Arribat
  • NOVEL MUTATED TISSUE PLASMINOGEN ACTIVATORS AND USES THEREOF
    Publication number: 20150050264
    Abstract: The present invention relates to mutated tissue plasminogen activators, and their use for treating thrombotic diseases.
    Type: Application
    Filed: September 7, 2012
    Publication date: February 19, 2015
    Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Denis VIVIEN, Jerome PARCQ, Denis VIVIEN, Jerome PARCQ
  • Methods of growing an embryo to a blastocyst stage of development
    Patent number: 8956865
    Abstract: The present invention relates generally to the fields of reproductive medicine. More specifically, the present invention relates to a novel human embryo co-culture system to improve human embryo growth in vitro and, consequently, increase pregnancy rates in infertile women undergoing in vitro fertilization (IVF) treatment. More particularly, the present invention relates to a method of growing an embryo to a blastocyst stage of development comprising the step of coculturing said embryo in the presence of a population of cumulus cells.
    Type: Grant
    Filed: August 11, 2011
    Date of Patent: February 17, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Montpellier 1, Centre Hospitalier Universitaire de Montpellier
    Inventors: Samir Hamamah, Said Assou
  • Aminoalkylsterol compounds with antitumoral and neuroprotective activity
    Patent number: 8957055
    Abstract: Sterol derivatives of formula (I) and a method for the production of the compounds, a medicament using one of the compounds and a pharmaceutical composition comprising the medicament.
    Type: Grant
    Filed: August 28, 2013
    Date of Patent: February 17, 2015
    Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Marc Poirot, Philippe De Medina, Sandrine Poirot
  • Detection of shed CD31, diagnosis of atherothrombosis and autoimmune disorders, and methods for analyzing signaling pathways
    Patent number: 8951743
    Abstract: The present invention stems from the finding that the extracellular domain of CD31 proteins present on blood leukocytes is shed and released in the circulation as a soluble form of CD31. A method for detecting shed CD31 is further disclosed. The invention therefore relates to a method for detecting a shed ectodomain of a transmembrane protein such as CD31 and to the use of such a method as a diagnostic tool. The invention further provides methods for determining whether a candidate protein is part of a molecular complex.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: February 10, 2015
    Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Giuseppina Caligiuri, Antonino Nicoletti
  • Mutants PF4 polypeptides exhibiting an increased anti-angiogenic activity
    Patent number: 8940702
    Abstract: The present invention pertains to PF4 muteins which comprise a substitution at position 67, e.g. a L67H substitution, compared to the sequence of the wild-type PF4 protein. Such PF4 muteins exhibit an increased anti-angiogenie activity and a reduced affinity for proteoglycans compared to the wild-type PF4 protein.
    Type: Grant
    Filed: July 26, 2010
    Date of Patent: January 27, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite de Bordeaux
    Inventors: Andreas Bikfalvi, Herve Prats, Cathy Quemener, Alexandre Dubrac
  • BIOMARKERS OF RENAL DISORDERS
    Publication number: 20150018383
    Abstract: The present invention is directed to the use of marker for Akt2 activation in podocytes as a biomarker to predict toxicity of mTOR inhibitors. Another aspect of the invention relates to a method for preventing graft rejection comprising administering a selective mTORC1 or Akt1 inhibitor in a subject in need thereof.
    Type: Application
    Filed: October 12, 2012
    Publication date: January 15, 2015
    Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Fabiola Terzi, Guillaume Canaud, Franck Ename
  • Method of hepatocellular carcinoma classification and prognosis
    Patent number: 8935102
    Abstract: Methodology for the in vitro classification and/or prognosis of hepatocellular carcinoma (HCC) from a HCC sample is based on the determination of the expression profile of particular gene combinations. For example, in one embodiment, a method comprises measuring the expression level in an HCC sample of at least 8 genes selected from the group consisting of: RAB1A, REG3A, NRAS, RAMP3, MERTK, PIR, EPHA1, LAMA3, G0S2, HN1, PAK2, AFP, CYP2C9, CDH2, HAMP, SAE1, ADH6, DCN, FLJ10159, ALDH1L1, IGF1, LECT2, SLC38A1, SPARCL1, CTNNA2, GLUL, LEF1, MATN2, MME, PFN2, SPINT2, TBX3, and FGFR2; b) calculating 6 subgroup distances from the expression profile; and c) classifying the HCC tumor in the subgroup for which the subgroup distance is the lowest, wherein the 6 subgroups G1, G2, G3, G4, G5, and G6 are defined by the presence (+) or absence (?) of their clinical and genetic features.
    Type: Grant
    Filed: November 30, 2006
    Date of Patent: January 13, 2015
    Assignee: Institut National de la Sante et de la Recherche Medicale (Inserm)
    Inventors: Jessica Zucman-Rossi, Aurélien De Reynies, David Rickman, Sandrine Boyault
  • METHOD FOR PROGNOSING THE AGE-AT-ONSET OF HUNTINGTON'S DISEASE
    Publication number: 20140377379
    Abstract: The present invention relates to the prediction of the age-at-onset of Huntington's disease. More specifically, it relates to the use of at least one FoxO-centered network related biallelic markers, preferably single nucleotide polymorphism (SNP) markers, in particular GSK-3? and/or TCERG1 and/or FOXO1 and/or FZD10 related biallelic markers, for prognosing the age-at-onset of symptoms of Huntington's disease in an individual at risk of suffering from said disease.
    Type: Application
    Filed: September 2, 2011
    Publication date: December 25, 2014
    Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventor: Christian Neri
  • NON HUMAN ANIMAL MODEL FOR ULCERATIVE COLITIS AND ITS MAIN COMPLICATIONS
    Publication number: 20140373186
    Abstract: The present invention relates to a non human model animal for ulcerative colitis and its main complications such as primary sclerosing cholangitis and colorectal cancer. More particularly, the present invention relates to a transgenic non human animal model for ulcerative colitis and its main complications such as primary sclerosing cholangitis, and colorectal cancer comprising a targeted disruption in the IL10 and NOX1 genes so that IL10 and NOX1 are not expressed in said animal.
    Type: Application
    Filed: April 13, 2012
    Publication date: December 18, 2014
    Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Eric Ogier-Denis, Xavier Treton, Fanny Daniel, Cecile Guichard, Eric Pedruzzi, Yoram Bouhnik, Yann Harnoy
  • Methods for treating breast cancer
    Patent number: 8900588
    Abstract: The present disclosure is directed to methods of treating and preventing breast cancer or recurrence of breast cancer with compositions comprising anti-progastrin antibodies.
    Type: Grant
    Filed: January 4, 2011
    Date of Patent: December 2, 2014
    Assignees: Les Laboratories Servier, Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS)
    Inventors: Jean-François Floch, Leïla Houhou, Françoise Cailler, Dominique Joubert, Frédéric Hollande